{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:40:27Z","timestamp":1793295627954,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.euros.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:19:18Z","timestamp":1789993158000},"page":"14-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PSMA PET\/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review"],"prefix":"10.1016","volume":"93","author":[{"given":"Jennifer","family":"Le Gu\u00e9velou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo F.W.","family":"Soeterik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Scheltema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Zattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Fasulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Preisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara Rodriguez","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Rovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Gomez","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Windisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"Stroomberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bourgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.09.003_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.09.003_b0010","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.09.003_b0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.09.003_b0020","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the Condor Phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2026.09.003_b0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JU.0000000000003493","article-title":"Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a Phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"210","author":"Jani","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.09.003_b0030","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.annonc.2025.08.004","article-title":"Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial","volume":"36","author":"Tripathi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0035","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.3390\/jcm13206221","article-title":"Ultralow prostate-specific antigen (PSA) levels and improved oncological outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with apalutamide: a real-world multicentre study","volume":"13","author":"L\u00f3pez-Abad","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.euros.2026.09.003_b0040","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euf.2025.03.019","article-title":"Prostate-specific antigen response as a prognostic factor for overall survival in patients with prostate cancer treated with androgen receptor pathway inhibitors: a systematic review and meta-analysis","volume":"11","author":"Miszczyk","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.09.003_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1391825","article-title":"EORTC 2238 \u201cde-escalate\u201d: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors","volume":"14","author":"Grisay","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0050","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222010","article-title":"A prognostic risk score for prostate cancer based on PSMA PET\u2013derived organ-specific tumor volumes","volume":"307","author":"Seifert","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.euros.2026.09.003_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112614","article-title":"Predictive value of quantitative parameters from dual-tracer FDG and PSMA PET\/CT for progression to castration resistance in patients with metastatic hormone-sensitive prostate cancer","volume":"195","author":"Xiang","year":"2026","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.euros.2026.09.003_b0060","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euros.2026.09.003_b0065","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-022-05970-y","article-title":"Flare on [18F]PSMA-1007 PET\/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients","volume":"50","author":"Malaspina","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euros.2026.09.003_b0070","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3390\/cancers14051329","article-title":"Impact of three-month androgen deprivation therapy on [68Ga]Ga-PSMA-11 PET\/CT indices in men with advanced prostate cancer-results from a pilot prospective study","volume":"14","author":"Tseng","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euros.2026.09.003_b0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13550-020-00723-0","article-title":"[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study","volume":"10","author":"Hober\u00fcck","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.euros.2026.09.003_b0080","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","article-title":"Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer","volume":"45","author":"Afshar-Oromieh","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euros.2026.09.003_b0085","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s00259-023-06321-1","article-title":"The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [68Ga]Ga-PSMA-11-PET\/CT in high-risk prostate cancer patients treated with definitive radiotherapy","volume":"50","author":"Onal","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euros.2026.09.003_b0090","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00259-019-04581-4","article-title":"The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients","volume":"47","author":"Onal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euros.2026.09.003_b0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41824-024-00212-w","article-title":"PSMA-PET\/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer","volume":"8","author":"Sheikh","year":"2024","journal-title":"EJNMMI Rep"},{"key":"10.1016\/j.euros.2026.09.003_b0100","article-title":"PSMA response evaluation in follow-up PSMA-PET\/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer","volume":"54","author":"Zang","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0105","first-page":"528","article-title":"PSMA PET\/CT to evaluate response to SBRT for prostate cancer bone metastases","volume":"26","author":"Sadetski","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.euros.2026.09.003_b0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s12094-022-03002-7","article-title":"Metabolic response after 68Ga-PSMA-PET\/CT-directed IGRT\/SBRT for oligometastases prostate cancer","volume":"25","author":"Gawish","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0115","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/pros.24775","article-title":"Impact of definitive radiotherapy on metabolic response measured with 68Ga-PSMA-PET\/CT in patients with intermediate-risk prostate cancer","volume":"84","author":"Onal","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2026.09.003_b0120","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/JU.0000000000004158","article-title":"Early prostate-specific antigen response by 6 months is predictive of treatment effect in metastatic hormone sensitive prostate cancer: an exploratory analysis of the Titan trial","volume":"212","author":"Roy","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.09.003_b0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41824-023-00178-1","article-title":"Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study","volume":"7","author":"Murthy","year":"2023","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1016\/j.euros.2026.09.003_b0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0135","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S1470-2045(22)00564-2","article-title":"Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01\/10): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Papachristofilou","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0140","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.eururo.2025.04.017","article-title":"Updated prostate cancer risk groups by prostate-specific membrane antigen positron emission tomography prostate cancer molecular imaging standardized evaluation (PPP2): results from an international multicentre registry study","volume":"88","author":"Karpinski","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.09.003_b0145","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1470-2045(26)00016-1","article-title":"New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study","volume":"27","author":"Karpinski","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0150","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2010.33.2999","article-title":"Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment","volume":"29","author":"Tzelepi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0155","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.09.003_b0160","article-title":"Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis of randomised controlled trials","volume":"54","author":"Roessler","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0165","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0170","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.09.003_b0175","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.09.003_b0180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euros.2026.09.003_b0185","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.euros.2026.09.003_b0190","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a Delphi analysis","volume":"89","author":"Herrmann","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326016356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326016356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:29:43Z","timestamp":1793294983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326016356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S2666168326016356"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.09.003","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA PET\/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}